{"address1": "3115 Merryfield Row", "address2": "Suite 300", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 465 6511", "website": "https://www.erasca.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan E. Lim M.D.", "age": 52, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 987696, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David M. Chacko M.D.", "age": 40, "title": "CFO & Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 666090, "exercisedValue": 0, "unexercisedValue": 948786}, {"maxAge": 1, "name": "Mr. Ebun S. Garner Esq., J.D.", "age": 52, "title": "General Counsel & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 607440, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael D. Varney Ph.D.", "age": 66, "title": "Chairman of Research & Development, Scientific Advisory Board Member and Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 86503, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nik  Chetwyn Ph.D.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lisa  Tesvich-Bonora Ph.D.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian L. Baker CPA, M.S.", "age": 57, "title": "Senior Vice President of Finance", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chandra D. Lovejoy M.S.", "age": 53, "title": "Chief Regulatory Affairs Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Shoemaker Ph.D.", "age": 43, "title": "Senior Vice President of Research", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shannon R. Morris M.D., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.37, "open": 1.35, "dayLow": 1.2, "dayHigh": 1.36, "regularMarketPreviousClose": 1.37, "regularMarketOpen": 1.35, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.36, "payoutRatio": 0.0, "beta": 1.222, "forwardPE": -1.6283784, "volume": 2033660, "regularMarketVolume": 2033660, "averageVolume": 1503700, "averageVolume10days": 2356190, "averageDailyVolume10Day": 2356190, "bid": 1.2, "ask": 1.21, "bidSize": 14, "askSize": 9, "marketCap": 341335520, "fiftyTwoWeekLow": 1.2, "fiftyTwoWeekHigh": 3.45, "fiftyDayAverage": 1.5697, "twoHundredDayAverage": 2.417625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 94915184, "profitMargins": 0.0, "floatShares": 201634202, "sharesOutstanding": 283265984, "sharesShort": 33096383, "sharesShortPriorMonth": 34521335, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.1168, "heldPercentInsiders": 0.123730004, "heldPercentInstitutions": 0.8649, "shortRatio": 26.19, "shortPercentOfFloat": 0.13270001, "impliedSharesOutstanding": 283265984, "bookValue": 1.495, "priceToBook": 0.8060201, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -161650000, "trailingEps": -0.69, "forwardEps": -0.74, "enterpriseToEbitda": -0.639, "52WeekChange": -0.44470048, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.205, "targetHighPrice": 7.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.92857, "targetMedianPrice": 5.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 298308992, "totalCashPerShare": 1.053, "ebitda": -148582000, "totalDebt": 51889000, "quickRatio": 9.575, "currentRatio": 9.836, "debtToEquity": 12.252, "returnOnAssets": -0.21215999, "returnOnEquity": -0.43678, "freeCashflow": -84591872, "operatingCashflow": -109417000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ERAS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Erasca, Inc.", "corporateActions": [], "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_595471999", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": -0.36469996, "fiftyDayAverageChangePercent": -0.23233737, "twoHundredDayAverageChange": -1.2126249, "twoHundredDayAverageChangePercent": -0.50157696, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-16", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "marketState": "PRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1626442200000, "regularMarketChange": -0.16499996, "regularMarketDayRange": "1.2 - 1.36", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1503700, "fiftyTwoWeekLowChange": 0.004999995, "fiftyTwoWeekLowChangePercent": 0.0041666627, "fiftyTwoWeekRange": "1.2 - 3.45", "fiftyTwoWeekHighChange": -2.245, "fiftyTwoWeekHighChangePercent": -0.6507246, "fiftyTwoWeekChangePercent": -44.470047, "epsTrailingTwelveMonths": -0.69, "epsForward": -0.74, "epsCurrentYear": -0.54737, "priceEpsCurrentYear": -2.201436, "longName": "Erasca, Inc.", "regularMarketChangePercent": -12.043793, "regularMarketPrice": 1.205, "displayName": "Erasca", "trailingPegRatio": null}